{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T13:22:05Z","timestamp":1768569725086,"version":"3.49.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The American Journal of the Medical Sciences"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1097\/maj.0b013e3182926a23","type":"journal-article","created":{"date-parts":[[2013,5,25]],"date-time":"2013-05-25T12:04:44Z","timestamp":1369483484000},"page":"455-461","source":"Crossref","is-referenced-by-count":13,"title":["Efficacy of Antitumor Necrosis Factor(\u03b1) Agents on Patients With Ankylosing Spondylitis"],"prefix":"10.1016","volume":"346","author":[{"given":"Lei","family":"Ren","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianbo","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renkuan","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lihua","family":"Wan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1097\/MAJ.0b013e3182926a23_bb0005","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1186\/ar592","article-title":"Therapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF-alpha therapy and other novel approaches","volume":"4","author":"Braun","year":"2002","journal-title":"Arthritis Res"},{"key":"10.1097\/MAJ.0b013e3182926a23_bb0010","first-page":"613","article-title":"Disability and handicap in rheumatoid arthritis and ankylosing spondylitis\u2013results from the German rheumatological database. German Collaborative Arthritis Centers","volume":"27","author":"Zink","year":"2000","journal-title":"J Rheumatol"},{"key":"10.1097\/MAJ.0b013e3182926a23_bb0015","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1093\/rheumatology\/36.7.766","article-title":"The outcome of ankylosing spondylitis: a study of 100 patients","volume":"36","author":"Gran","year":"1997","journal-title":"Br J Rheumatol"},{"key":"10.1097\/MAJ.0b013e3182926a23_bb0020","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1002\/1529-0131(199806)41:6<1119::AID-ART20>3.0.CO;2-0","article-title":"Reference centile charts for measures of disease activity, functional impairment, and metrology in ankylosing spondylitis","volume":"41","author":"Taylor","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1097\/MAJ.0b013e3182926a23_bb0025","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/1529-0131(199908)12:4<247::AID-ART3>3.0.CO;2-H","article-title":"Health-related quality of life in ankylosing spondylitis: a survey of 175 patients","volume":"12","author":"Ward","year":"1999","journal-title":"Arthritis Care Res"},{"key":"10.1097\/MAJ.0b013e3182926a23_bb0030","first-page":"S16","article-title":"Mortality, course of disease and prognosis of patients with ankylosing spondylitis","volume":"20","author":"Braun","year":"2002","journal-title":"Clin Exp Rheumatol"},{"key":"10.1097\/MAJ.0b013e3182926a23_bb0035","first-page":"688","article-title":"The natural history of ankylosing spondylitis. Does it burn out?","volume":"20","author":"Kennedy","year":"1993","journal-title":"J Rheumatol"},{"key":"10.1097\/MAJ.0b013e3182926a23_bb0040","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/art.1780380407","article-title":"Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis","volume":"38","author":"Braun","year":"1995","journal-title":"Arthritis Rheum"},{"key":"10.1097\/MAJ.0b013e3182926a23_bb0045","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1093\/rheumatology\/36.1.38","article-title":"Comparative cytokine gene expression in synovial tissue of early rheumatoid arthritis and seronegative spondyloarthropathies","volume":"36","author":"Canete","year":"1997","journal-title":"Br J Rheumatol"},{"key":"10.1097\/MAJ.0b013e3182926a23_bb0050","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1093\/rheumatology\/33.10.927","article-title":"Serum cytokines (IL-6, TNF-alpha, IL-1 beta and IFN-gamma) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity","volume":"33","author":"Gratacos","year":"1994","journal-title":"Br J Rheumatol"},{"key":"10.1097\/MAJ.0b013e3182926a23_bb0055","doi-asserted-by":"crossref","first-page":"6602","DOI":"10.4049\/jimmunol.151.11.6602","article-title":"Influence of a recombinant human soluble tumor necrosis factor receptor FC fusion protein on type II collagen-induced arthritis in mice","volume":"151","author":"Wooley","year":"1993","journal-title":"J Immunol"},{"key":"10.1097\/MAJ.0b013e3182926a23_bb0060","doi-asserted-by":"crossref","first-page":"982","DOI":"10.7326\/0003-4819-135-11-200112040-00010","article-title":"Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses","volume":"135","author":"Kjaergard","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1097\/MAJ.0b013e3182926a23_bb0065","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S0140-6736(98)01085-X","article-title":"Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?","volume":"352","author":"Moher","year":"1998","journal-title":"Lancet"},{"key":"10.1097\/MAJ.0b013e3182926a23_bb0070","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jama.1995.03520290060030","article-title":"Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials","volume":"273","author":"Schulz","year":"1995","journal-title":"JAMA"},{"key":"10.1097\/MAJ.0b013e3182926a23_bb0075","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1136\/bmj.39465.451748.AD","article-title":"Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study","volume":"336","author":"Wood","year":"2008","journal-title":"BMJ"},{"key":"10.1097\/MAJ.0b013e3182926a23_bb0080","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"10.1097\/MAJ.0b013e3182926a23_bb0085","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1002\/art.11017","article-title":"Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis","volume":"48","author":"Brandt","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1097\/MAJ.0b013e3182926a23_bb0090","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1136\/ard.2004.020875","article-title":"Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis","volume":"63","author":"Calin","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1097\/MAJ.0b013e3182926a23_bb0095","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1002\/art.11325","article-title":"Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial","volume":"48","author":"Davis","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1097\/MAJ.0b013e3182926a23_bb0100","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1136\/ard.2010.139261","article-title":"Efficacy of etanercept on rheumatic signs and pulmonary function tests in advanced ankylosing spondylitis: results of a randomised double-blind placebo-controlled study (SPINE)","volume":"70","author":"Dougados","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1097\/MAJ.0b013e3182926a23_bb0105","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJMoa012664","article-title":"Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha","volume":"346","author":"Gorman","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1097\/MAJ.0b013e3182926a23_bb0110","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1136\/ard.2006.056747","article-title":"Etanercept 50mg once weekly is as effective as 25mg twice weekly in patients with ankylosing spondylitis","volume":"65","author":"van der Heijde","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1097\/MAJ.0b013e3182926a23_bb0115","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/S0140-6736(02)08215-6","article-title":"Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial","volume":"359","author":"Braun","year":"2002","journal-title":"Lancet"},{"key":"10.1097\/MAJ.0b013e3182926a23_bb0120","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1136\/ard.2004.022582","article-title":"Infliximab in combination with methotrexate in active ankylosing spondylitis: a clinical and imaging study","volume":"64","author":"Marzo-Ortega","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1097\/MAJ.0b013e3182926a23_bb0125","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/art.20852","article-title":"Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT)","volume":"52","author":"van der Heijde","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1097\/MAJ.0b013e3182926a23_bb0130","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.3899\/jrheum.091042","article-title":"A double-blind, placebo-controlled trial of low dose infliximab in ankylosing spondylitis","volume":"37","author":"Inman","year":"2010","journal-title":"J Rheumatol"},{"key":"10.1097\/MAJ.0b013e3182926a23_bb0135","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1002\/art.21913","article-title":"Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial","volume":"54","author":"van der Heijde","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1097\/MAJ.0b013e3182926a23_bb0140","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1002\/art.23969","article-title":"Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial","volume":"58","author":"Inman","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1097\/MAJ.0b013e3182926a23_bb0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta11280","article-title":"Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation","volume":"11","author":"McLeod","year":"2007","journal-title":"Health Technol Assess"},{"key":"10.1097\/MAJ.0b013e3182926a23_bb0150","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1002\/art.24001","article-title":"Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period","volume":"59","author":"Braun","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1097\/MAJ.0b013e3182926a23_bb0155","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1007\/s00296-009-1157-3","article-title":"A 2-year comparative open label randomized study of efficacy and safety of etanercept and infliximab in patients with ankylosing spondylitis","volume":"30","author":"Giardina","year":"2010","journal-title":"Rheumatol Int"},{"key":"10.1097\/MAJ.0b013e3182926a23_bb0160","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1136\/annrheumdis-2011-200308","article-title":"Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised, placebo-controlled GO-RAISE study","volume":"71","author":"Braun","year":"2012","journal-title":"Ann Rheum Dis"}],"container-title":["The American Journal of the Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962915304584?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962915304584?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,11]],"date-time":"2024-05-11T05:28:26Z","timestamp":1715405306000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002962915304584"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["S0002962915304584"],"URL":"https:\/\/doi.org\/10.1097\/maj.0b013e3182926a23","relation":{},"ISSN":["0002-9629"],"issn-type":[{"value":"0002-9629","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12]]}}}